{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:08:44Z","timestamp":1771542524202,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.amjcard.2018.10.035","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T02:21:11Z","timestamp":1541470871000},"page":"382-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-967X","authenticated-orcid":false,"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Charytan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-6364","authenticated-orcid":false,"given":"Yuyin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-2791","authenticated-orcid":false,"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2018.10.035_bib0001","first-page":"S28","article-title":"Comprehensive medical evaluation and assessment of comorbidities","volume":"41","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0002","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCOUTCOMES.115.002365","article-title":"Predicting adverse outcomes after myocardial infarction among patients with diabetes mellitus","volume":"9","author":"Arnold","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0004","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0006","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehv588","article-title":"Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure","volume":"37","author":"van Veldhuisen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0007","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2215\/CJN.02590315","article-title":"Urinary biomarkers and risk of ESRD in the atherosclerosis risk in communities study","volume":"10","author":"Foster","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0008","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00125-014-3389-3","article-title":"Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus","volume":"58","author":"Fufaa","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0009","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2215\/CJN.05280517","article-title":"Kidney biomarkers and decline in eGFR in patients with type 2 diabetes","volume":"13","author":"Garlo","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1053\/j.ajkd.2011.12.009","article-title":"Longitudinal progression trajectory of GFR among patients with CKD","volume":"59","author":"Li","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0011","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","volume":"162","author":"White","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0012","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0013","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0014","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0015","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/dom.12905","article-title":"Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial","volume":"19","author":"Bergmark","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0016","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","article-title":"Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)","volume":"135","author":"Cavender","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0017","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2337\/diacare.20.5.725","article-title":"Model of complications of NIDDM. I. Model construction and assumptions","volume":"20","author":"Eastman","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0018","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1002\/sim.7139","article-title":"Discrimination slope and integrated discrimination improvement - properties, relationships and impact of calibration","volume":"36","author":"Pencina","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0019","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.7326\/0003-4819-142-7-200504050-00008","article-title":"Cystatin C concentration as a risk factor for heart failure in older adults","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0021","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2337\/dc13-1910","article-title":"Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S","volume":"37","author":"Tsai","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/clc.22556","article-title":"Comparison of risk prediction with the CKD-EPI and MDRD equations in non-ST-segment elevation acute coronary syndrome","volume":"39","author":"Flores-Blanco","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0024","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2215\/CJN.08560816","article-title":"Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: the CRIC study","volume":"12","author":"Park","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2017.4228","article-title":"Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial","volume":"3","author":"Scirica","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0026","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jdi.12142","article-title":"Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus","volume":"5","author":"Mori","year":"2014","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2018.10.035_bib0028","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/dc16-0303","article-title":"Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918320502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914918320502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:04:25Z","timestamp":1762077865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914918320502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0002914918320502"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.10.035","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}